BenevolentAI
BenevolentAI is a clinical-stage AI drug discovery company that applies a proprietary knowledge graph and machine learning platform to drug target identification, molecule design, and repurposing for pharmaceutical and biotechnology partners.
- Company typePrivate
- Founded2013
- HeadquartersLondon, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What BenevolentAI does
BenevolentAI is a clinical-stage AI drug discovery company that builds and applies a proprietary artificial intelligence platform to identify novel drug targets, design molecules, and repurpose existing drugs. The company's core technology is a decade-invested biomedical knowledge graph combined with proprietary ontologies that structure relationships across scientific literature, clinical data, patents, and other biomedical sources. The platform supports workflows from target identification through clinical candidate selection and is positioned to address structural inefficiencies in pharmaceutical R&D, including per-drug development costs exceeding $2 billion, timelines of 12-15 years, and clinical trial failure rates above 90%. BenevolentAI's most prominent real-world validation was its identification of baricitinib as a COVID-19 therapeutic, which subsequently received FDA Emergency Use Authorization.
The company serves pharmaceutical and biotechnology companies through strategic collaborations and co-development partnerships, and also operates its own internal pipeline. Named partners include AstraZeneca, with whom BenevolentAI is applying its platform to respiratory and cardiovascular disease, and the Institute of Cancer Research, with whom it identified drug combinations for DIPG brain cancer. BenevolentAI's monetization model is not publicly disclosed but is consistent with industry norms for clinical-stage AI biotechs: upfront and milestone-based collaboration revenue from pharma partners, with optional downstream royalties on partnered programs. The company operates through wholly-owned subsidiaries in the UK (London, Cambridge), the United States, and is domiciled in Luxembourg as a société anonyme.
BenevolentAI was founded in 2013 and raised approximately $292 million in disclosed equity funding across rounds in 2015, 2018, and 2019, with Temasek leading the most recent disclosed round. The company was previously publicly listed on Euronext Amsterdam under the ticker BAI. In March 2025, BenevolentAI delisted from Euronext Amsterdam and merged with Osaka Holdings S.à r.l., becoming a privately held entity following shareholder approval at an Extraordinary General Meeting. Prior to this transaction, the company experienced clinical setbacks and restructuring amid broader sector pressure on AI drug discovery valuations.
BenevolentAI firmographics
Firmographics- Name
- BenevolentAI
- Legal name
- BenevolentAI
- Website
- https://benevolent.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- BenevolentAI is a clinical-stage AI drug discovery company that applies a proprietary knowledge graph and machine learning platform to drug target identification, molecule design, and repurposing for pharmaceutical and biotechnology partners.
- Ownership category
- akta.pro rank
BenevolentAI industry classification
Industry- Product category
- AI-Enabled Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where BenevolentAI is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
BenevolentAI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations
BenevolentAI product offering
Product offeringCore offering
BenevolentAI builds and operates an AI-powered drug discovery and life science intelligence platform centered on a decade of investment in a proprietary knowledge graph and ontologies. The platform integrates scientific literature, clinical data, and patents to support target identification, molecule design, drug repurposing, and clinical candidate selection for pharmaceutical and biotechnology partners.
Product overview
BenevolentAI offers a unified AI drug discovery platform centered on its proprietary knowledge graph and ontology system. The platform is described as a next-generation life science intelligence solution that enables scientists and researchers to leverage cutting-edge AI and machine learning across drug discovery and development workflows. The system integrates diverse biomedical data sources to support complex R&D decisions from target identification through clinical development.
Differentiator
Problem solved
Functional benefit
Products and services
- BenevolentAI Platform An AI-powered drug discovery and life science intelligence platform that integrates a knowledge graph and proprietary ontologies to support target identification, molecule design, drug repurposing, and clinical candidate selection for pharmaceutical and biotechnology partners across the R&D pipeline.
Quantifiable outcome
- BenevolentAI identified Baricitinib for COVID-19 which received FDA Emergency Use Authorization
- +1 more outcomes
Companies that use BenevolentAI
Customer profileSegments1 record
Ideal customer profiles1 record
BenevolentAI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature1 record
BenevolentAI partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- AstraZenecacoreBenevolentAI collaborated with AstraZeneca to apply AI to target respiratory and cardiovascular conditions, combining BenevolentAI's AI platform with AstraZeneca's pharmaceutical expertise.
- Osaka HoldingscoreExscientia's over $1 billion merger with BenevolentAI was reported as a significant M&A activity in the sector, though the actual merger was with Osaka Holdings S.à r.l.
- The Institute of Cancer ResearchcoreBenevolentAI collaborated with The Institute of Cancer Research to identify drug combinations for DIPG brain cancer using their AI-driven drug repurposing platform.
Recent moves6 records
Expansion highlights4 records
BenevolentAI competitors and assessment
Company assessmentDirect peers
- Exscientia: Direct peer in AI-driven small-molecule drug discovery; both companies combine AI platforms with pharma partnerships to accelerate target identification and molecule design. Exscientia is explicitly named alongside BenevolentAI in sector coverage and itself underwent a merger transaction in 2025.
- Insilico Medicine: Direct peer using generative AI and deep learning for end-to-end drug discovery, from target identification through preclinical candidate nomination. Insilico is named in the same next-tier cohort of AI drug discovery specialists as BenevolentAI.
- Recursion Pharmaceuticals: Direct peer applying AI and high-throughput experimental automation to drug discovery; both companies target the same pharma partnership and pipeline economics. Recursion is a US-based comparable in scale and ambition.
- Schrödinger, Inc. Direct peer combining physics-based computational chemistry with AI/ML for drug discovery, serving large pharma customers. Comparable hybrid platform approach and target pharma customer base.
- Atomwise: Direct peer in AI-driven small-molecule drug discovery, particularly virtual screening and hit identification. Comparable technology positioning and pharma collaboration model.
- XtalPi: Direct peer combining AI, quantum physics, and robotics for drug discovery and crystal structure prediction. Comparable platform approach serving global pharma customers.
Broad incumbents
- Isomorphic Labs: Alphabet-owned AI drug discovery lab founded by DeepMind; broader incumbent with deeper capital base pursuing AI-native drug design. Comparable end-market but with significantly larger financial and computational resources.
Emerging players
- Verge Genomics: Emerging player applying AI to genomics-driven drug discovery, with overlap on target identification. Smaller and earlier-stage but competes for similar pharma collaboration and venture capital.
- Owkin: Emerging player applying AI/ML to biomedical research and drug development, with overlap in AI-driven target and biomarker discovery for pharma partners. More health-data focused but adjacent platform.
- Absci: Emerging player combining generative AI with wet-lab validation for biologic and small-molecule drug discovery. Comparable AI-first discovery approach, particularly relevant given BenevolentAI's exploration of biologic and complex-disease targets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
BenevolentAI social profiles
Digital presenceBenevolentAI financial estimates
Financial estimateRevenue estimate
Valuation estimate
BenevolentAI leadership team
Management profileNumber of profiles
Profiles9 records
BenevolentAI subsidiaries and ownership
Company hierarchySubsidiaries5 records
BenevolentAI funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BenevolentAI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BenevolentAI
What does BenevolentAI do?
BenevolentAI builds and operates an AI-powered drug discovery and life science intelligence platform centered on a decade of investment in a proprietary knowledge graph and ontologies. The platform integrates scientific literature, clinical data, and patents to support target identification, molecule design, drug repurposing, and clinical candidate selection for pharmaceutical and biotechnology partners.
Is BenevolentAI a public or private company?
BenevolentAI is a private company. It is classified as corporate owned and is currently acquired.
When was BenevolentAI founded?
BenevolentAI was founded in 2013. It employs 101 to 250 people.
Where is BenevolentAI based?
BenevolentAI is headquartered in London, United Kingdom, in the Europe region.
Who are BenevolentAI's main competitors?
Direct peers on record are Exscientia, Insilico Medicine, Recursion Pharmaceuticals, Schrödinger, Inc., Atomwise and XtalPi. Isomorphic Labs is listed as a broad incumbent. Emerging players are Verge Genomics, Owkin and Absci.
Does BenevolentAI have an API?
No public API is recorded for BenevolentAI.
What industry is BenevolentAI in?
BenevolentAI's product category is AI-Enabled Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.